JOVITA EZIRIM-SALAMIALOFOJE: Open Payments
NPI 1114320124 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,065 in 143 payments from 10 companies in 2025. Trend: 2023 $43,489 · 2024 $28,973 · 2025 $20,065
Speaker / faculty: $15,022Food & beverage: $4,241Travel & lodging: $401Consulting: $395Education: $7
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 41 | $16,615 |
| Janssen Pharmaceuticals, Inc | 21 | $807 |
| Alkermes, Inc. | 17 | $717 |
| Otsuka America Pharmaceutical, Inc. | 22 | $558 |
| E.R. Squibb & Sons, L.L.C. | 11 | $522 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $456 |
| Neurocrine BioSciences, Inc. | 7 | $186 |
| Luye Pharma (USA) Ltd. | 5 | $92 |
| ABBVIE INC. | 5 | $92 |
| Lundbeck LLC | 1 | $21 |
Products named: AUSTEDO XR, UZEDY, INVEGA SUSTENNA, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, COBENFY, LYBALVI.
Industry payments across CA — which companies pay providers there.
